Testing AK150 for Advanced Solid Tumors
Part of Cancer clinical trials.
This is a Phase 1 study testing a new drug called AK150 in patients with advanced cancer that has spread or hasn't responded well to standard treatments. The goal is to find the right dose and see how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 75 years old
- Advanced or metastatic solid tumor (cancer that has spread) that hasn't responded to standard treatment or for which standard treatment isn't available
- At least one measurable tumor visible on imaging (RECIST v1.1 criteria)
- Good overall health with performance status 0 or 1 (able to do daily activities with minimal limitations)
- Expected lifespan of at least 3 months
- No active cancer elsewhere in your body within the past 3 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AK132 for people with advanced solid tumors. It looks at safety and how well the drug works, and may be an option if you have not already tried treatments targeting CD47 or Claudin18.2.
This study tests an experimental drug (AK146D1) for people with advanced solid tumors that are no longer responding to standard treatments. The goal is to see if it is safe and effective.
This trial tests a new drug called AK146D1 for people with advanced solid tumors that have not responded to standard treatments or no longer work. The goal is to see if it is safe and effective.
This trial tests a new drug called AK138D1 for people with advanced solid tumors. It aims to see if the drug is safe and how well it works, especially for tumors that haven't been treated with HER3-targeted therapy before.
This trial tests a new drug called AK131 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and can help slow or shrink the cancer.
This phase 1 trial tests a new drug called AK137, which is designed to help your immune system better attack cancer cells. It is for people with advanced tumors that have not been helped by standard therapies. The goal is to find out if AK137 is safe and effective.
Hear when a new Advanced Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.